Lipid-lowering Therapies in Vietnamese Chronic Kidney Disease Population
Status:
Unknown status
Trial end date:
2020-10-15
Target enrollment:
Participant gender:
Summary
This study aims to determine the mechanisms underlying dyslipidemia in chronic kidney disease
(CKD) and effect of lipid-lowering therapies in patients with CKD via parameters of lipid,
oxidative stress, tryptophan delegation as well as renal function and side effects. Thirty
3,4 CKD patients with low-density lipoprotein (LDL) > 100 mg/mL (2,59mmol/l), randomly
receive three different LDL lipid-lowering therapies: Simvastatin (40 mg/day) or
ezetimibe/simvastatin combination (10/20 mg/day or 10/40 mg/day).
Phase:
Phase 4
Details
Lead Sponsor:
Hue University of Medicine and Pharmacy
Collaborator:
Università degli Studi di Sassari
Treatments:
Ezetimibe Ezetimibe, Simvastatin Drug Combination Simvastatin